Search results

Skip to results

Type

Status

Last updated

Showing 1 result for fulvestrant non nice approved indications

  1. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA421